
(MedPage Today) — LONG BEACH, Calif. — Outcomes in neovascular age-related macular degeneration (nAMD) failed to improve with the addition of a multitargeted trap fusion protein to anti-VEGF therapy, according to a randomized trial reported…
Source link : https://www.medpagetoday.com/meetingcoverage/asrs/116806
Author :
Publish date : 2025-08-03 00:28:00
Copyright for syndicated content belongs to the linked
Source.